AMENDMENT TO THE CLAIMS:

The following listing will replace all previous versions and listings of claims in the present application.

1-38. (Canceled)

39. (Currently amended) A genetically engineered ~~methylotrophic yeast~~*Pichia* strain, wherein said strain is engineered to express (1) a *Trichoderma reesei* α-1,2-mannosidase or a functional part thereof, (2) an N-acetylglucosaminyltransferase I (GnTI) or a functional part thereof, and (3) a β-1,4-galactosyltransferase (GalT) or a functional part thereof, and the genomic OCH1 gene of said strain is disrupted.

40. (Canceled)

41. (Currently amended) The strain of claim 4~~0~~39, wherein said strain is a *Pichia pastoris* strain.

42. (Previously presented) The strain of claim 39, wherein said α-1,2-mannosidase or said functional part thereof is targeted to the ER or the Golgi of said strain.

43. (Previously presented) The strain of claim 42, wherein said α-1,2-mannosidase or said functional part thereof is engineered to contain an ER-retention signal.

44. (Previously presented) The strain of claim 43, wherein said ER-retention signal comprises the peptide HDEL (SEQ ID NO: 1).

45. (Previously presented) The strain of claim 39, wherein said GnTI or said functional part thereof is of an origin of a species selected from the group consisting of rabbit, rat, human, plant, insect, nematode and protozoa.

46. (Previously presented) The strain of claim 45, wherein said GnTI or said functional part thereof is of a human origin.

47. (Previously presented) The strain of claim 39, wherein said GnTI or said functional part thereof is engineered to contain a Golgi-retention signal.

48. (Previously presented) The strain of claim 47, wherein said Golgi-retention signal comprises SEQ ID NO: 11.

49. (Previously presented) The strain of claim 39, wherein said GalT or said functional part thereof is of an origin of a species selected from the group consisting of rabbit, rat, human, plant, insect and nematode.

50. (Previously presented) The strain of claim 49, wherein said GalT or said functional part thereof is of a human origin.

51. (Previously presented) The strain of claim 39, wherein said GalT or said functional part thereof is engineered to contain a Golgi-retention signal.

52. (Previously presented) The strain of claim 51, wherein said Golgi-retention signal comprises SEQ ID NO: 11.

53. (Previously presented) The strain of claim 39, wherein said α-1,2-mannosidase or said functional part is expressed from a promoter selected from the group consisting of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

54. (Previously presented) The strain of claim 39, wherein said GnTI or said functional part is expressed from a promoter selected from the group consisting of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

55. (Previously presented) The strain of claim 39, wherein said GalT or said functional part is expressed from a promoter selected from the group consisting of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

56. (Previously presented) The strain of claim 39, wherein α-1,2-mannosidase or said functional part is expressed from the AOX1 promoter of *Pichia pastoris*, and said GnTI or said functional part is expressed from the GAP promoter of *Pichia pastoris*.

57. (New) The strain of claim 39, wherein said functional part of said α-1,2-mannosidase comprises the catalytic domain of said α-1,2-mannosidase.

58. (New) The strain of claim 39, wherein said functional part of said GnT1 comprises the catalytic domain of said GnT1.

59. (New) The strain of claim 39, wherein said functional part of said GalT comprises the catalytic domain of said GalT.